[go: up one dir, main page]

SG10201501535UA - Treatment of lupus nephritis using laquinimod - Google Patents

Treatment of lupus nephritis using laquinimod

Info

Publication number
SG10201501535UA
SG10201501535UA SG10201501535UA SG10201501535UA SG10201501535UA SG 10201501535U A SG10201501535U A SG 10201501535UA SG 10201501535U A SG10201501535U A SG 10201501535UA SG 10201501535U A SG10201501535U A SG 10201501535UA SG 10201501535U A SG10201501535U A SG 10201501535UA
Authority
SG
Singapore
Prior art keywords
laquinimod
treatment
lupus nephritis
nephritis
lupus
Prior art date
Application number
SG10201501535UA
Inventor
Asi Haviv
Nora Tarcic
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201501535U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG10201501535UA publication Critical patent/SG10201501535UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201501535UA 2010-03-03 2011-03-02 Treatment of lupus nephritis using laquinimod SG10201501535UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33936310P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
SG10201501535UA true SG10201501535UA (en) 2015-04-29

Family

ID=44531856

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201501535UA SG10201501535UA (en) 2010-03-03 2011-03-02 Treatment of lupus nephritis using laquinimod
SG2012063483A SG183512A1 (en) 2010-03-03 2011-03-02 Treatment of lupus nephritis using laquinimod

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012063483A SG183512A1 (en) 2010-03-03 2011-03-02 Treatment of lupus nephritis using laquinimod

Country Status (20)

Country Link
US (5) US8889661B2 (en)
EP (1) EP2542078B1 (en)
JP (3) JP2013521303A (en)
KR (3) KR20160129093A (en)
CN (1) CN102791130B (en)
AU (2) AU2011223692A1 (en)
BR (1) BR112012021905A2 (en)
CA (1) CA2791691A1 (en)
CL (1) CL2012002423A1 (en)
CO (1) CO6630082A2 (en)
EA (1) EA201290837A1 (en)
ES (1) ES2558556T3 (en)
IL (1) IL250357A0 (en)
MX (1) MX337614B (en)
NZ (1) NZ602510A (en)
PE (2) PE20181523A1 (en)
PH (1) PH12012501739A1 (en)
SG (2) SG10201501535UA (en)
WO (1) WO2011109526A1 (en)
ZA (1) ZA201207129B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
UA104005C2 (en) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2010147665A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
ME02414B (en) * 2009-07-30 2016-09-20 Teva Pharma TREATMENT OF MORBUS CROHN WITH LAQUINIMOD
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
CA2791709A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013000333A (en) 2010-07-09 2013-02-26 Teva Pharma N-ETIL-N-PHENYL-1,2-DIHIDRO-4-HYDROXI-5-CHLORINE-1-METHYL-2-OXOQUINOLI NA-3-CARBOXAMIDE DEUTERADA, SALTS AND USES OF THE SAME.
HK1199820A1 (en) 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (en) 2012-02-03 2014-09-24 Teva Pharma USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
EP2744498A4 (en) 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL -1,2-DIHYDRO -4,5-DI-HYDROXY -1-METHYL -2-OXO-3-QUINOLINE CARBOXAMIDE, ITS PREPARATION AND USE
TW201350467A (en) 2012-05-08 2013-12-16 Teva Pharma N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammation with laquinimod
WO2014004733A1 (en) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1220125A1 (en) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CA3076036A1 (en) * 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US20250195492A1 (en) * 2022-03-04 2025-06-19 Novartis Ag Use of iptacopan for the treatment of lupus nephritis

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (en) 1976-02-11 1977-09-09 Roussel Uclaf NEW DERIVATIVES OF 3-QUINOLEINE CARBOXYLIC ACID, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS A MEDICINAL PRODUCT
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (en) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (en) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (en) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6395750B1 (en) 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (en) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
ES2282667T3 (en) 2002-06-25 2007-10-16 Merck Frosst Canada Ltd. PDE4 INHIBITORS 8- (BIARIL) QUINOLINAS.
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005000246A2 (en) 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (en) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
US20060004019A1 (en) 2004-04-01 2006-01-05 Ivan Lieberburg Steroid sparing agents and methods of using same
US20080048181A1 (en) * 2004-06-10 2008-02-28 Tatsuo Tanaka Organic Semiconductor Thin Film, Organic Semiconductor Device, Organic Thin Film Transistor and Organic Electronic Luminescence Element
WO2006029036A2 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EA014238B1 (en) 2005-01-31 2010-10-29 Мерк Сероно Са N-hydroxyamide derivatives and use thereof
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
JP5203956B2 (en) 2005-10-26 2013-06-05 メルク セローノ ソシエテ アノニム Sulfonamide derivatives and their use for the regulation of metalloproteinases
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
US8410115B2 (en) 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
ES2752137T3 (en) 2006-02-28 2020-04-03 Biogen Ma Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007103112A2 (en) 2006-03-03 2007-09-13 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
AU2007227609A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using CD4 antibodies
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20080090897A1 (en) 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
JP5216769B2 (en) 2006-08-17 2013-06-19 ザ・ユニバーシティ・オブ・シカゴ Treatment of inflammatory diseases
AU2007338771A1 (en) 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ES2422479T3 (en) * 2007-03-27 2013-09-11 Zymogenetics Inc Combination of inhibition of BLyS and mycophenolate mofetil for the treatment of autoimmune diseases
US8138201B2 (en) 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009053070A1 (en) 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2009133468A1 (en) 2008-04-28 2009-11-05 Actavis Group Ptc Ehf Improved process for preparing quinoline-3-carboxamide derivatives
US8354428B2 (en) 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
UA104005C2 (en) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-oxo-1,2-dihydro-quinoline modulators of immune function
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Method for treating progressive multiple sclerosis
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
WO2010147665A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
ME02414B (en) 2009-07-30 2016-09-20 Teva Pharma TREATMENT OF MORBUS CROHN WITH LAQUINIMOD
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
EP2542080B1 (en) 2010-03-03 2016-08-31 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
CA2791709A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013000333A (en) 2010-07-09 2013-02-26 Teva Pharma N-ETIL-N-PHENYL-1,2-DIHIDRO-4-HYDROXI-5-CHLORINE-1-METHYL-2-OXOQUINOLI NA-3-CARBOXAMIDE DEUTERADA, SALTS AND USES OF THE SAME.
JP5934202B2 (en) 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド 5-Chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses thereof
JP5396349B2 (en) * 2010-08-10 2014-01-22 日立ビークルエナジー株式会社 Secondary battery
EP2648732A4 (en) 2010-12-07 2014-04-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2014001050A (en) 2011-07-28 2014-04-14 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate.
SG10201606204TA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta

Also Published As

Publication number Publication date
KR20150135552A (en) 2015-12-02
US20110218179A1 (en) 2011-09-08
US20170368053A1 (en) 2017-12-28
CA2791691A1 (en) 2011-09-09
JP2017165740A (en) 2017-09-21
ZA201207129B (en) 2014-06-25
CL2012002423A1 (en) 2012-12-21
PE20130613A1 (en) 2013-06-23
US20170258780A1 (en) 2017-09-14
AU2016204466A1 (en) 2016-07-21
BR112012021905A2 (en) 2015-09-29
JP2013521303A (en) 2013-06-10
US20150038508A1 (en) 2015-02-05
WO2011109526A1 (en) 2011-09-09
EP2542078A4 (en) 2013-07-10
EA201290837A1 (en) 2013-05-30
CN102791130A (en) 2012-11-21
IL250357A0 (en) 2017-03-30
AU2011223692A1 (en) 2012-10-25
PH12012501739A1 (en) 2017-08-23
KR20130006640A (en) 2013-01-17
EP2542078A1 (en) 2013-01-09
US20180140594A1 (en) 2018-05-24
HK1177878A1 (en) 2013-08-30
JP2016128464A (en) 2016-07-14
CN102791130B (en) 2015-02-25
SG183512A1 (en) 2012-09-27
KR20160129093A (en) 2016-11-08
PE20181523A1 (en) 2018-09-24
NZ602510A (en) 2014-11-28
EP2542078B1 (en) 2015-10-07
US8889661B2 (en) 2014-11-18
CO6630082A2 (en) 2013-03-01
MX337614B (en) 2016-03-10
MX2012010070A (en) 2012-10-03
ES2558556T3 (en) 2016-02-05

Similar Documents

Publication Publication Date Title
ZA201207129B (en) Treatment of lupus nephritis using laquinimod
ZA201207125B (en) Treatment of lupus arthritis using laquinimod
ZA201304280B (en) Treatment of jak2-mediated conditions
IL252699A0 (en) Treatment of multiple sclerosis with laquinimod
IL220876A0 (en) Treatment of cardiac conditions
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201301601B (en) Treatment of diseases
GB201018147D0 (en) Method of treatment
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL225896A0 (en) Treatment of mecp2-associated disorders
IL256026B (en) Methods of treatment
GB201003920D0 (en) Method of treatment
ZA201207496B (en) Treatment of chicory
ZA201103007B (en) Treatment of tantalium-and/or niobium-containing compounds
GB201018149D0 (en) Method of treatment
IL222690A0 (en) Treatment of autoimmune diseases
ZA201207497B (en) Treatment of chicory
EP2585103A4 (en) Method of treatment
GB201020015D0 (en) Method of treatment
ZA201008686B (en) Treatment of animals
EG26997A (en) Tube for treatment of syrngomylia
GB201009614D0 (en) Therapeutic use of compounds
GB201014736D0 (en) Treatment of hepatitis C
HU1000688D0 (en) Use of trifluoro-phal
GB201005071D0 (en) Method of treatment